Upregulation of T-bet and tight junction molecules by Bifidobactrium longum improves colonic inflammation of ulcerative colitis

Inflammatory Bowel Diseases

Volumn 15, Issue 11, 2009, Pages 1617-1618

  Takeda, Yasuhiro ^a   Nakase, Hiroshi ^a   Namba, Kazuyoshi ^b   Inoue, Satoko ^a   Ueno, Satoru ^a   Uza, Norimitsu ^a   Chiba, Tsutomu ^a  

^a KYOTO UNIVERSITY   (Japan)

^b Nutritional Science Institute   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIFIDOBACTERIUM LONGUM EXTRACT; CYTOKINE; MESALAZINE; PROBIOTIC AGENT; TRANSCRIPTION FACTOR T BET; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; CLINICAL ARTICLE; CLINICAL TRIAL; COLITIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE DURATION; DRUG MECHANISM; DRUG RESPONSE; FEMALE; HUMAN; HUMAN TISSUE; INTESTINE BIOPSY; LETTER; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROCTITIS; REMISSION; TIGHT JUNCTION; TREATMENT DURATION; ULCERATIVE COLITIS; UPREGULATION;

ADULT; BIFIDOBACTERIUM; COLITIS, ULCERATIVE; FEMALE; HUMANS; MALE; MIDDLE AGED; PILOT PROJECTS; PROBIOTICS; REMISSION INDUCTION; T-BOX DOMAIN PROTEINS; TIGHT JUNCTIONS; TREATMENT OUTCOME; UP-REGULATION;

EID: 72649091421     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1002/ibd.20861     Document Type: Letter

References (6)

1. Isaacs K, Herfarth H. Role of probiotic therapy in IBD. Inflamm Bowel Dis. 2008;14:1597-1605.
2. Furrie E, Macfarlane S, Kennedy A, et al. Symbiotic therapy (Bifidobacterium longum/Synergy 1) initiates resolution of inflammation in patients with active ulcerative colitis: a randomized controlled pilot trial. Gut. 2005;54:242-249. (Pubitemid 40139241)
3. Ogata T, Nakamura T, Anjitsu, et al. Effect of Bifidobacterium longum BB536 administration on the intestinal environment, defection frequency and fecal characteristics of human volunteers. Biosci Microflora. 1997;16:53-58.
4. Nakase H, Mikami S, Chiba T. Alteration of CXCR4 expression and Th1/Th2 balance of peripheral CD4-positive T cells can be a biomarker for leukocytapheresis therapy for patients with refractory ulcerative colitis. Inflamm Bowel Dis. (in press).
5. Kasahara K, Nakase H, Uza N, et al. Administration of PEG-interferon to a patient with ulcerative colitis and chronic hepatitis C correlated with reduced colonic inflammation and reversal of peripheral Th1/Th2 ratios. Case Rep Gastroenterol. 2007;1:157-161.
6. Takahashi N, Kitazawa H, Shimosato T, et al. An immunostimulatory DNA sequence from a probiotic strain of Bifidobacterium longum inhibits IgE production in vitro. FEMS Immunol Med Mirobiol. 2006;46:461-469.